<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00540553</url>
  </required_header>
  <id_info>
    <org_study_id>SAR109935</org_study_id>
    <nct_id>NCT00540553</nct_id>
  </id_info>
  <brief_title>Study to Test Safety, Tolerability and Blood Levels of GSK971086 After 1 Dose &amp; 7 Days of Dosing in Healthy Adult Males</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo Controlled, Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GSK971086 After a Single Dose and 7 Days of Repeat Dosing in Healthy Adult Male Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This research study is the first administration of GSK971086 in humans. The purpose of this
      study is to assess the safety and tolerability of GSK971086, as well as, how much GSK971086
      is in your blood after different doses
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2007</start_date>
  <completion_date type="Actual">April 2008</completion_date>
  <primary_completion_date type="Actual">April 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse events:</measure>
    <time_frame>all visits</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>hematology, clinical chemistry, urinalysis:</measure>
    <time_frame>Part A Days -2,2,3,14,28 &amp; Part B Days -2,2,5,8,14,21,35</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>vital signs &amp; 12-lead ECGs:</measure>
    <time_frame>Part A Days -2-3,7,28 &amp; Part B Days -2-9,14,35</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>GSK 971086 Plasma blood level:</measure>
    <time_frame>art A Days 1,2,3,7,14,21,28 &amp; Part B Days 1-9,14,21,28,35</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PBone &amp; muscle biomarkers:</measure>
    <time_frame>Part A Days 1,2,7,14,21,28 &amp; Part B Days 1,3,8,14,21,28,35</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">126</enrollment>
  <condition>Healthy Subjects</condition>
  <condition>Androgen Deficiency</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GSK971086</intervention_name>
    <other_name>placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males between 18 and 50 years of age (inclusive), at the time of signing the informed
             consent form.

          -  Healthy, as determined by the Investigator, based on medical evaluations performed
             during the Screening Period including medical history, physical examination, clinical
             laboratory tests, and cardiac monitoring.

          -  Subjects must agree to use an acceptable method of contraception as described in the
             protocol. These criteria must be followed from the time of the first dose of study
             drug until completion of the Final Safety and PK Visit in the Follow-up Period.

          -  Body weight and Body Mass Index (BMI) within the ranges defined in the protocol.

          -  Subject is able to understand and comply with protocol requirements, instructions, and
             protocol-stated restrictions, including those listed in the informed consent form.

          -  Subject has given informed consent to participate in the study as indicated by
             providing a signed and dated written informed consent form prior to any study
             procedures.

        Exclusion Criteria:

          -  Subjects with a history of clinically significant endocrine, gastrointestinal,
             hepatic,cardiovascular, neurological, haematological, immunological, renal,
             respiratory, or genitourinary abnormalities or diseases.

          -  Subjects with a history at any time in the past of coronary artery disease, congestive
             heart failure, angina, myocardial infarction, any cardiac surgery, valvular heart
             disease, clinically significant arrhythmia, dyspnea, pulmonary edema, stroke, or
             transient ischemic attack. ECG exclusion criteria as defined in the protocol.

          -  Subjects with a history of malignancy that is not in complete remission for at least 5
             years, 1 year for non-melatonomatous skin carcinoma.

          -  Subjects with values outside the specified ranges in the protocol for the following
             Key Clinical Laboratory Tests must be excluded from the study: liver function tests,
             renal function, electrolytes, metabolic, muscle and haematology.

          -  Prostate Specific Antigen (PSA) &gt;3.0ng/mL at Screening or subjects with a family
             history of early onset prostate cancer or multiple members with prostate cancer.

          -  History of serious psychological disorders such as schizophrenia, uncontrolled bipolar
             disorder, and suicidal behaviour.

          -  History of drug or alcohol abuse within 5 years prior to the Screening Period.

          -  Positive test for illicit drugs or alcohol during Screening assessments. A minimum
             list of illicit drugs that will be screened for are listed in the protocol.

          -  History of regular alcohol consumption averaging &gt;14 drinks/week within 12 months
             prior to the Screening Period.

          -  A positive test for Human Immunodeficiency Virus (HIV), Hepatitis B surface antigen,
             or Hepatitis C antibody upon screening, or at any time prior to the Screening Period.

          -  Use of prescription or non-prescription drugs, including vitamins, herbal and dietary
             supplements (including St John's Wort) within 14 days or 5 half-lives (whichever is
             longer) prior to the first dose of study drug, however, the use of acetaminophen,
             ibuprofen, and naproxen will be allowed, as described in the protocol.

          -  The subject has participated in a clinical trial and has received a drug or a new
             chemical entity within 30 days or 5 half-lives, or twice the duration of the
             biological effect of any drug (whichever is longer) prior to the first dose of current
             study drug.

          -  History of drug or other allergy that, in the opinion of the Investigator,
             contraindicates their participation.

          -  Where participation in study would result in donation of blood in excess of 500mL
             within a 56 day period.

          -  History of sensitivity to heparin or heparin-induced thrombocytopenia.

          -  Consumption of red wine, Seville oranges, grapefruit or grapefruit juice from 7 days
             prior to the first dose of study drug until check-out from the clinic on the last day
             of the Treatment Period.

          -  Unwillingness to adhere to the study Lifestyle Guidelines as described in the
             protocol.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Evansville</city>
        <state>Indiana</state>
        <zip>47714</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 4, 2007</study_first_submitted>
  <study_first_submitted_qc>October 4, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 8, 2007</study_first_posted>
  <last_update_submitted>March 15, 2012</last_update_submitted>
  <last_update_submitted_qc>March 15, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 19, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>SARM,</keyword>
  <keyword>FTIH,</keyword>
  <keyword>pharmacokinetics</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

